Treatment of giant-cell arteritis, a literature review

References

• Ly KH, Liozon E, Fauchais AL, Vidal E. [Pathophysiology of giant cell arteritis]. Rev Med Interne. 2013;34:392–402.
   PubMed Web of Science ®Google Scholar
• Chaigne-Delalande S, de Menthon M, Lazaro E, Mahr A. [Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspects]. Presse Med. 2012;41:955–65.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372:234–45.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatoly (Oxford). 2012;51:151–6.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period: GCA epidemiology in Minnesota. Arthritis Rheum. 2004;51:264–8.
   PubMed Web of Science ®Google Scholar
• Lee JL, Naguwa SM, Cheema GS, Gershwin ME. The geo-epidemiology of temporal (giant cell) arteritis. Clin Rev Allergy Immunol. 2008;35:88–95.
   PubMed Web of Science ®Google Scholar
• Nordborg E, Bengtsson BA. Epidemiology of biopsy-proven giant cell arteritis (GCA). J Intern Med. 1990;227:233–6.
   PubMed Web of Science ®Google Scholar
• Gran JT, Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94. J Rheumatol. 1997;24:1739–43.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970–1991. Arthritis Rheum. 1995;38:369–73.
   PubMed Web of Science ®Google Scholar
• Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990–2001. Ann Rheum Dis. 2006;65:1093–8.
   PubMed Web of Science ®Google Scholar
• Sailler L, Pugnet G, Bienvenu B. [Treatment of giant cell arteritis]. Rev Med Interne. 2013;34:431–7.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79:283–92.
   PubMed Web of Science ®Google Scholar
• Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015;74:129–35.
   PubMed Web of Science ®Google Scholar
• Assie C, Janvresse A, Plissonnier D, Levesque H, and Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90:40–51.
   PubMed Web of Science ®Google Scholar
• Tomasson G, Peloquin C, Mohammad A, Love TJ, Zhang Y, Choi HK, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: a cohort study. Ann Intern Med. 2014;160:73–80.
   PubMed Web of Science ®Google Scholar
• Samson M, Jacquin A, Audia S, Daubail B, Devilliers H, Petrella T, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 2015;86:216–21.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Martinez-Dubois C, Agudo M, Pompei O, Blanco R, Llorca J. Giant cell arteritis: epidemiology, diagnosis, and management. Curr Rheumatol Rep. 2010;12:436–42.
   PubMedGoogle Scholar
• Pipitone N, Boiardi L, Salvarani C. Are steroids alone sufficient for the treatment of giant cell arteritis? Best Pract Res Clin Rheumatol. 2005;19:277–92.
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49:1594–7.
   PubMed Web of Science ®Google Scholar
• Dasgupta B.. Giant Cell Arteritis Guideline Development Group. Concise guidance: diagnosis and management of giant cell arteritis. Clin Med (Lond). 2010;10:381–6.
   PubMed Web of Science ®Google Scholar
• Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, et al. Management of giant cell arteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016;37:154–65.
   PubMed Web of Science ®Google Scholar
• Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68:318–23.
   PubMed Web of Science ®Google Scholar
• Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49:703–8.
   PubMed Web of Science ®Google Scholar
• JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75:474–503.
   PubMed Web of Science ®Google Scholar
• Barrier JH, Magadur G, Hamidou M, Letellier P, Dupond JL, Liozon F, et al. Utilisation des bolus de méthylprednisolone à la phase initiale de la maladie de Horton. Analyse des complications, rechutes et décès à un an de suivi. Rev Med Interne. 1993;14:444.
   Google Scholar
• Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27:1484–91.
   PubMed Web of Science ®Google Scholar
• Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310–8.
   PubMed Web of Science ®Google Scholar
• Scheurer RA, Harrison AR, Lee MS. Treatment of vision loss in giant cell arteritis. Curr Treat Options Neurol. 2012;14:84–92.
   PubMed Web of Science ®Google Scholar
• Hayreh SS, and Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol. 2012;32:278–87.
   PubMed Web of Science ®Google Scholar
• Fardet L. [Glucocorticoid-induced adverse events in patients with giant cell arteritis or polymyalgia rheumatica]. Rev Med Interne. 2013;34:438–43.
   PubMed Web of Science ®Google Scholar
• Sarnes E, Crofford L, Watson M, Dennis G, Kan H, and Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33:1413–32.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé. Prévention, diagnostic et traitement de l’ostéoporose. 2006.
   Google Scholar
• Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–7.
   PubMed Web of Science ®Google Scholar
• Roux C, Orcel P. [Steroid induced osteoporosis: prevention and treatment]. Rev Med Interne. 2003;24:384–8.
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62:1515–26.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update. J Bone Miner Metab. 2014;32:337–50.
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, and Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?. Ann Rheum Dis. 1996;55:218–23.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309–18.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495–501.
   PubMed Web of Science ®Google Scholar
• Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, and Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–14.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56:2789–97.
   PubMed Web of Science ®Google Scholar
• de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43:105–12.
   PubMed Web of Science ®Google Scholar
• De Silva M, and Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986;45:136–8.
   PubMed Web of Science ®Google Scholar
• Le Guennec P, Dromer C, Sixou L, Marc V, Coustals P, and Fournié B. [Treatment of Horton disease. Value of synthetic antimalarials. Apropos of a retrospective study of 36 patients]. Rev Rhum Ed Fr 1993. 1994;61:485–90.
   PubMedGoogle Scholar
• David-Chaussé J, Dehais J, and Leman A. [Results of a regional survey on the treatment of rhizomelic pseudopolyarthritis and temporal arteritis. Apropos of 242 cases treated by various modalities with synthetic antimalarials, corticoids and non-steroidal anti-inflammatory agents]. Rev Rhum Mal Osteoartic. 1983;50:563–71.
   PubMedGoogle Scholar
• Sailler L, Lapeyre-Mestre M, Geffray M, Letellier P, Liozon F, de la Roque, et al. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial [abstract]. Arthritis Rheum. 2009;1972.
   Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621–30.
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puéchal X, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73:2074–81.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67:625–30.
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Janikashvili N, Bonnotte B. Is TNF-α really involved in giant cell arteritis pathogenesis? Ann Rheum Dis. 2014;73:e1
   PubMed Web of Science ®Google Scholar
• Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36:1286–94.
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 2012;64:3788–98.
   PubMed Web of Science ®Google Scholar
• Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol. 2013;25:3–9.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011;38:2080–1.
   PubMed Web of Science ®Google Scholar
• Vinit J, Bielefeld P, Muller G, Besancenot JF. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012;79:317–8.
   PubMed Web of Science ®Google Scholar
• Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol. 2012;31:1263–5.
   PubMed Web of Science ®Google Scholar
• Christidis D, Jain S, Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Rep 2011;2011. doi:10.1136/bcr.04.2011.4135.
   PubMedGoogle Scholar
• Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, and Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011;141:w13156
   PubMed Web of Science ®Google Scholar
• Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011;70:1874–5.
   PubMed Web of Science ®Google Scholar
• Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012 Nov;64(11):1720–9.
   PubMed Web of Science ®Google Scholar
• Adler S, Reichenbach S, Kuchen S, Wermelinger F, Dan D, Villiger P, et al. Tocilizumab for the treatment of giant cell arteritis—a randomized placebo-controlled trial [abstract]. Arthritis Rheum. 2015;67:3926–627.
   Google Scholar
• Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562
   PubMedGoogle Scholar
• Langford CA, Cuthbertson D, Ytterberg S, Khalidi N, Monach P, Carette S, et al. A randomized double-blind trial of abatacept and glucocorticoids for the treatment of giant cell arteritis [abstract]. Arthritis Rheum. 2015;67(suppl 10).
   Web of Science ®Google Scholar
• Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121:906–15.
   PubMed Web of Science ®Google Scholar
• Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum. 2012;64:2001–11.
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flynn E, McCarthy G, Murphy C, Veale D. Ustekinumab for the treatment of refractory giant cell arteritis [abstract]. Arthritis Rheum. 2015;67:2593–5.
   Web of Science ®Google Scholar
• Ly K-H, Stirnemann J, Liozon E, Michel M, Fain O, Fauchais A-L. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine 2014;81:76–8.
   PubMed Web of Science ®Google Scholar
• Lee MS, Smith SD, Galor A, and Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006;54:3306–9.
   PubMed Web of Science ®Google Scholar
• Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, and Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332–7.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Blanco R, Rodríguez-Valverde V, Martínez-Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41:1497–504.
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Gómez-Vaquero C, García-Gómez C, Roig-Vilaseca D, Juanola X, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26:S57–S62.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Della Bella C, Cimino L, Macchioni P, Formisano D, Bajocchi G, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford). 2009;48:250–3.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Rodriguez LAG, Maguire A, Castellsague J, and Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192:376–83.
   PubMed Web of Science ®Google Scholar
• Aviña-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52:68–75.
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, López-Hoyos M, Narvaez J, Muñoz-Cacho P. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014;13:788–94.
   PubMed Web of Science ®Google Scholar
• Lally L, Pernis A, Narula N, Huang WT, Spiera R. Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis. Rheumatology (Oxford). 2015;54:554–8.
   PubMed Web of Science ®Google Scholar
• Isgro J, Gupta S, Jacek E, Pavri T, Duculan R, Kim M, et al. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:1592–602.
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum. 2007;36(5):322–7.
   PubMed Web of Science ®Google Scholar
• García-Martínez A, Hernández-Rodríguez J, Grau JM, and Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51:674–8.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Yano T, Matsumoto Y, Numano F, Nakajima N, Yasuda K, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49:594–8.
   PubMed Web of Science ®Google Scholar
• De Vries F, Bracke M, Leufkens HGM, Lammers J-WJ, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208–14.
   PubMed Web of Science ®Google Scholar
• Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MTB, Fliers E, et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab. 2009;94:2743–50.
   PubMed Web of Science ®Google Scholar
• Généreau T, Tiev K, Rabhi M, Baret M, and Cabane J. [Physiopathological data of Horton's syndrome]. Presse Med. 2004;33:33–40.
   PubMed Web of Science ®Google Scholar
• Liozon E, Herrmann FR, Ly K, Jauberteau MO, Loustaud V, Soria P, et al. [Risk factors for irreversible cerebral ischemia complications from Horton’s disease: prospective study of 178 patients]. Rev Med Interne. 2001;22:30–41.
   PubMed Web of Science ®Google Scholar
• van der Pas R, Leebeek FWG, Hofland LJ, de Herder WW, and Feelders RA. Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf). 2013;78:481–8.
   PubMed Web of Science ®Google Scholar